- Home
- ENIC vs LEGN Comparison
ENIC vs LEGN Comparison
Compare ENIC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENIC | LEGN |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.9B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ENIC | LEGN |
|---|---|---|
| Price | $4.28 | $29.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $61.33 |
| AVG Volume (30 Days) | 515.2K | ★ 2.3M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $96,491.22 | $42.68 |
| Revenue Next Year | $2.63 | $30.52 |
| P/E Ratio | $101.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $16.24 |
| 52 Week High | $4.74 | $45.30 |
Technical Indicators
Market Signals| Indicator | ENIC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 66.13 |
| Support Level | $4.17 | $25.01 |
| Resistance Level | $4.40 | $29.69 |
| Average True Range (ATR) | 0.12 | 1.99 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 24.99 | 88.29 |
Price Performance
Historical ComparisonAbout ENIC Enel Chile S.A. (Each representing 50 shares of)
Enel Chile SA is an electricity utility company engaged, through its subsidiaries and affiliates, in the generation, transmission, and distribution of electricity across Chile. The Company operates through two main segments: the Generation Business, which includes companies that own and operate power plants supplying electricity to the grid and generates the majority of revenue; and the Distribution and Network Business, which consists of companies operating under public utility concessions to distribute electricity to end customers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.